ACCC appeals $1.7m Nurofen penalty

Consumer watchdog says fine is inadequate deterrent. The Australian Competition and Consumer Commission (ACCC) is appealing the federal court’s decision to fine Reckitt Benckiser $1.7 million for its Nurofen Specific Pain products range. The commission is calling for its original penalty suggestion of $6 million, “in order to send a strong deterrence message” against misrepresentation of pharmaceutical

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Opioids have minimal benefit in low back pain
Next Harm minimisation efforts pay big dividends